Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
Incyte(INCY) stock is priced at $101.00, giving the company a market capitalization of 19.77B. It carries a P/E multiple of 17.23.
As of 2025-12-22, Incyte(INCY) stock has fluctuated between $98.99 and $103.95. The current price stands at $101.00, placing the stock +2.0% above today's low and -2.8% off the high.
Incyte(INCY) shares are trading with a volume of 1.97M, against a daily average of 2.45M.
In the last year, Incyte(INCY) shares hit a 52-week high of $109.28 and a 52-week low of $53.56.
In the last year, Incyte(INCY) shares hit a 52-week high of $109.28 and a 52-week low of $53.56.
INCY News
Incyte (INCY) announced the Japan Ministry of Health, Labour and Welfare approval of Zynyz in combination with carboplatin and paclitaxel for the first-line tre...
New insider activity at Incyte ( (INCY) ) has taken place on December 18, 2025. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund leve...
In mid-December 2025, Incyte announced that the European Commission approved Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or r...
Analyst ratings
46%
of 28 ratingsMore INCY News
Incyte (INCY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and po...
Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in combination with Revlimid (lenali...
Incyte (INCY) announced that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of adult patients wit...
Wondering if Incyte is still a smart buy after its big run, or if most of the upside is already priced in? This breakdown will help you decide whether the curre...